HIMSHims & Hers Health, Inc.

NYSE forhims.com


$ 21.05 $ 0.84 (4.16 %)    

Thursday, 11-Jul-2024 15:59:57 EDT
QQQ $ 492.14 $ -11.03 (-2.19 %)
DIA $ 397.90 $ 0.37 (0.09 %)
SPY $ 556.42 $ -4.84 (-0.86 %)
TLT $ 93.53 $ 0.90 (0.97 %)
GLD $ 223.19 $ 3.89 (1.77 %)
$ 21.05
$ 20.79
$ 21.04 x 200
$ 0.00 x 0
$ 20.64 - $ 21.32
$ 5.65 - $ 25.74
6,380,325
na
4.83B
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-06-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 02-27-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-22-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-27-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-29-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 td-cowen-maintains-buy-on-hims--hers-health-raises-price-target-to-25

TD Cowen analyst Jonna Kim maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target from $15 to $25.

 piper-sandler-maintains-neutral-on-hims--hers-health-raises-price-target-to-18

Piper Sandler analyst Korinne Wolfmeyer maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and raises the price tar...

Core News & Articles

https://news.bloomberglaw.com/health-law-and-business/ozempic-may-lower-risk-of-obesity-related-cancers-study-finds

Core News & Articles

https://www.usatoday.com/story/opinion/2024/07/02/biden-sanders-prescription-drug-cost-ozempic-wegovy/74232827007/

 hims--hers-health-stock-is-sliding-thursday-whats-going-on

Hunterbrook releases a bearish report alleging that Hims & Hers sells knockoff GLP-1 weight loss drugs and relies on a sing...

 jefferies-maintains-hold-on-hims--hers-health-raises-price-target-to-23

Jefferies analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from ...

Core News & Articles

NVDAMUTSLAHIMSBBAIRIVNAAPLWAYWBAData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment 

 watching-hims--hers-health-shares-hunterbrook-issues-short-report

https://hntrbrk.com/hims/

 avidity-biosciences-and-cleanspark-were-among-the-10-biggest-mid-cap-stock-gainers-last-week-june-9-june-15-are-these-in-your-portfolio

Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, Cle...

 b-of-a-securities-maintains-buy-on-hims--hers-health-raises-price-target-to-26

B of A Securities analyst Michael Cherny maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target...

Core News & Articles

https://www.statnews.com/2024/06/11/google-verily-glp1-weight-loss-drugs-lightpath-onduo/